发明名称 POTENT LNA OLIGONUCLEOTIDES FOR THE INHIBITION OF HIF-1A EXPRESSION
摘要 <p>The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5'-(Tx GxGxcsasasa sgscsastscs csTXGXT-3' and 5'-(G X)TXTXascsts gscscststsc sTXTXA-3', wherein capital letters designate a beta-D-oxy-LNA nucleotide analogue, small letters designate a 2-deoxynucleotide, underline designates either a beta-D-oxy-LNA nucleotide analogue or a 2-deoxynucleotide, subscript "s" designates a phosphorothioate link between neighbouring nucleotides/LNA nucleotide analogues, and subscript "x" designates either a phosphorothioate link or a phosphorodiester link between neighbouring nucleotides/LNA nucleotide analogues, and wherein the sequence is optionally extended by up to five 2-deoxynucleotide units. The LNA oligonucleotides are useful for modulating the expression of hypoxia-inducible factor-la (HIF-1a), e.g. in the treatment of cancer diseases, inhibiting angiogenesis, inducing apoptosis, preventing cellular proliferation, or treating an angiogenic disease, e.g. diabetic retinopathy, macular degeneration (ARMD), psoriasis, rheumatoid arthritis and other inflammatory diseases.</p>
申请公布号 KR20070094891(A) 申请公布日期 2007.09.27
申请号 KR20077012303 申请日期 2005.11.09
申请人 SANTARIS PHARMA A/S 发明人 RASMUSSEN FRANK WINTHER;WESTERGAARD MAJKEN;HANSEN HENRIK FRYDENLUND;THRUE CHARLOTTE ALBAEK
分类号 C12N15/00;C12N15/113 主分类号 C12N15/00
代理机构 代理人
主权项
地址